Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02955251 · ClinicalTrials.gov registry record · Phase 1
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02955251 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 61 participants.
The verdict
NCT02955251, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.
Interventions
- DRUG Nivolumab
- DRUG ABBV-428
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2019-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02955251
The ClinicalTrials.gov registry entry for NCT02955251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02955251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02955251 about?
NCT02955251 is a clinical study titled "A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors". This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced s...
What is the current status of trial NCT02955251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2016-11-18. Estimated completion is 2019-10-29.
What interventions are being tested in trial NCT02955251?
The interventions under investigation include: Nivolumab (DRUG), ABBV-428 (DRUG).
Who is sponsoring clinical trial NCT02955251?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.